Reprint
Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies
Edited by
October 2019
160 pages
- ISBN978-3-03921-614-7 (Paperback)
- ISBN978-3-03921-615-4 (PDF)
This book is a reprint of the Special Issue Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies that was published in
Biology & Life Sciences
Medicine & Pharmacology
Public Health & Healthcare
Summary
Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies is a Special Issue of the International Journal of Neonatal Screening. Sickle cell disease is one of the most common inherited blood disorders, with a huge impact on health care systems due to high morbidity and high mortality associated with the undiagnosed disease. Newborn screening helps to make the diagnosis early and to prevent fatal complications and diagnostic odysseys. This book gives an overview of diagnostic standards in newborn screening for sickle cell disease and examples of existing newborn screening programs.
Format
- Paperback
License
© 2019 by the authors; CC BY-NC-ND license
Keywords
newborn screening; sickle cell disease; India; tribal; non-tribal; Guthrie spots; cord blood; automated HPLC; (recommended) screening panel; policy making; harmonisation; patient advocacy; Sickle Cell Disease; ‘Getting to Outcomes’; newborn screening); sub-Saharan Africa; Nigeria; Kaduna State; implementation science; public health engagement; glucose-6-phosphate dehydrogenase; G6PD deficiency; point-of-care; diagnostics; malaria; Plasmodium vivax; screening; sickle cell disease; newborn; mass spectrometry; hemoglobinopathies; newborn screening; methods; review; sickle cell disease; neonatal screening program; registry; birth prevalence; newborn screening; sickle cell disease; hemoglobinopathy; laboratory methods; neonatal screening; hemoglobin pattern; HPLC; IEF; capillary electrophoresis; sickle cell disease; high performance liquid chromatography (HPLC); β-globin gene; sickle cell disease; newborn screening; Caribbean; newborn screening; sickle cell disease; MALDI-TOF; mass spectrometry; thalassemia; prevention; neonatal screening; sickle cell disease; hemoglobinopathies; sickle cell disorder; patient organisations; patient representatives; service users; sickle cell and thalassaemia screening programme; health policy; screening; sickle cell disease; newborn; thalassemia; burden of disease; newborn screening; hemoglobinopathies; sickle cell disease (SCD); pathophysiology; hydroxyurea/hydroxycarbamide; haemolysis; vaso-occlusive crisis; acute chest syndrome; end-organ damage; bone marrow transplant; anaemia; foetal haemoglobin; gene therapy for haemoglobinopathies; n/a